Article info
PDFMultiple sclerosis
Research paper
Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events
- Correspondence to Professor Massimiliano Calabrese, Neurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico “G.B. Rossi” Borgo Roma, Piazzale L A Scuro, Verona 1037134, Italy; massimiliano.calabrese{at}univr.it
Citation
Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events
Publication history
- Received April 11, 2017
- Revised July 8, 2017
- Accepted August 6, 2017
- First published August 26, 2017.
Online issue publication
November 28, 2017
Article Versions
- Previous version (26 August 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.